Comments for The Cross-Border Biotech Blog

Comment on Assessing Potential Market Share for a New Drug: Part 14 of Valuation and Other Biotech Mysteries by samson

samson — Sat, 10 Dec 2011 04:09:15 +0000

what alot of excellent information you have provided,great site and great info
thanks

Comment on Biotech Trends in 2010: Top Three Reasons Why Biotech Companies Should Use Social Media by Mike

Mike — Mon, 14 Nov 2011 19:37:01 +0000

We use social media to project our company as a brand. Like other biotech companies we are always on a hunt for new customers and social media has played a vital role in getting them. Most amazing part of using social media promotion is its easier for customers to get in contact with you. I think its not just limited to biotech companies but any company can use social media to find new customers.

Comment on Monday Biotech Deal Review: September 12, 2011 by Monday Biotech Deal Review: November 14, 2011 « The Cross-Border Biotech Blog

Mon, 14 Nov 2011 15:45:27 +0000

[...] outstanding common shares of Afexa Life Sciences Inc. pursuant to its previously announced offer (covered here). Shareholders will receive $0.85 per share in cash. Valeant intends to privatize Afexa, as set out [...]

Comment on Monday Biotech Deal Review: September 26, 2011 by Monday Biotech Deal Review: November 14, 2011 « The Cross-Border Biotech Blog

Mon, 14 Nov 2011 15:45:12 +0000

[...] announced public offering of 9,767,500 ($0.25) units and 7,663,870 ($0.25) common shares (covered here) for proceeds of $5,441,875. The units are comprised of one common share and a one-half (5-year, [...]

Comment on Friday Science Review: September 2, 2011 by stem cells xenograft | StemEnhance™ and StemFlo™ | Stem Cell Enhancer

stem cells xenograft | StemEnhance™ and StemFlo™ | Stem Cell Enhancer — Wed, 26 Oct 2011 00:17:10 +0000

[...] = ''; } Isolation of Stem Cells from Human Pancreatic Cancer XenograftsFriday Science Review: September 2, 2011 var analyticsFileTypes = ['']; var analyticsEventTracking = 'enabled'; var _gaq = _gaq || [...]

Comment on Monday Biotech Deal Review: May 2, 2011 by Monday Biotech Deal Review: October 17, 2011 « The Cross-Border Biotech Blog

Mon, 17 Oct 2011 22:06:45 +0000

[...] and Gruppo Angelini have completed the previously announced restructuring of their partnership (covered here), whereby Labopharm has granted Angelini an exclusive license and rights related to OLEPTRO™ in [...]

Comment on Monday Biotech Deal Review: August 22, 2011 by Monday Biotech Deal Review: October 17, 2011 « The Cross-Border Biotech Blog

Mon, 17 Oct 2011 22:06:25 +0000

[...] has closed the second tranche of its previously announced non-brokered private placement (covered here) of 240,000 ($0.35) units for proceeds of $84,000, to be used to enhance Gemoscan’s cash and [...]

Comment on Potential Rewards from Successful Drug Development: Part 13 of Valuation and Other Biotech Mysteries by Assessing Potential Market Share for a New Drug: Part 14 of Valuation and Other Biotech Mysteries « The Cross-Border Biotech Blog

Wed, 12 Oct 2011 12:01:12 +0000

[...] the previous post, we looked at epidemiology and pricing to estimate the market size for a new drug. As we continue [...]

Comment on Monday Biotech Deal Review: September 26, 2011 by Monday Biotech Deal Review: October 3, 2011 « The Cross-Border Biotech Blog

Monday Biotech Deal Review: October 3, 2011 « The Cross-Border Biotech Blog — Mon, 03 Oct 2011 14:47:49 +0000

[...] International inc. (TSX: EKO) has closed its previously announced $6 million financing (covered here), consisting of a $4 million credit facility and $2 million in convertible [...]

Comment on Monday Biotech Deal Review: August 22, 2011 by Monday Biotech Deal Review: October 3, 2011 « The Cross-Border Biotech Blog

Monday Biotech Deal Review: October 3, 2011 « The Cross-Border Biotech Blog — Mon, 03 Oct 2011 14:47:44 +0000

[...] GES) has closed the first tranche of its previously announced non-brokered private placement (covered here), issuing 1,771,428 ($0.35) units for proceeds of $620,000, to be used to enhance Gemoscan’s cash [...]